Table 2.
Characteristics of 11-18 studies included in the meta-analysis
| Author (year) | Ethnicity | Cancer type | Sample size | Age | Cutoff (hTERT) | Outcome | HR | 95% CI | NOS score | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Lower | Upper | |||||||||
| Nencha U (2016)* | Caucasian | GBM (IV) | 651 | NA | Mutant versus wildtype | OS | 1.46 | 1.19 | 1.80 | 7 |
| Gao K (2015) | Asian | Gliomas (I-IV) | 389 | Adult | Mutant versus wildtype | OS | 1.39 | 1.13 | 2.17 | 7 |
| Mutant (C228T) versus wildtype | OS | 7.66 | 2.21 | 26.61 | ||||||
| Mutant (C250T) versus wildtype | OS | 2.5 | 0.57 | 10.91 | ||||||
| Zhang Z (2015) | Asian | Gliomas (II-III) | 295 | NA | Mutant versus wildtype | OS | 1.158 | 0.746 | 1.796 | 7 |
| PFS | 1.139 | 0.756 | 1.716 | |||||||
| Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.890 | 0.349 | 2.267 | ||||||
| Spiegl-Kreinecker S (2015) | Caucasian | GBM (IV) | 126 | NA | Mutant versus wildtype | OS | 1.683 | 1.048 | 2.703 | 8 |
| Simon M (2015) | Caucasian | GBM (IV) | 176 | Adult | Mutant versus wildtype | OS | 2.05 | 1.30 | 3.23 | 7 |
| Mosrati MA (2015) | Caucasian | GBM (IV) | 146 | NA | Mutant (C228T) versus wildtype | OS | 4.04 | 1.55 | 10.51 | 7 |
| Mutant (C250T) versus wildtype | OS | 3.7 | 1.3 | 10.51 | ||||||
| Labussière M (2015) | Caucasian | Glioms (II-IV) | 807 | Adult | Mutant versus wildtype | OS | 1.497 | 1.071 | 2.092 | 8 |
| PFS | 1.766 | 1.299 | 2.401 | 9 | ||||||
| Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.57 | 0.32 | 1.00 | ||||||
| Chan AK (2015)* | Asian | Gliomas (II-III) | 236 | NA | Mutant/IDH mutant versus wildtype/IDH mutant | OS | 0.46 | 0.24 | 0.88 | 9 |
| Mutant/IDH wildtype versus wildtype/IDH wildtype | OS | 2.70 | 1.36 | 5.37 | ||||||
| Astrocytoma (II-III) | Mutant/IDH wildtype versus wildtype/IDH wildtype | OS | 2.42 | 1.14 | 5.15 | |||||
*Data extracted form survival curve. Data of hTERT promoter mutation (n=22) and hTERT expression difference (n=7) in glioma patients. GBM=Glioblastoma; hTERT=Human telomerase reverse transcriptase; IDH=Iso-citrate dehydrogenase; PFS=Progression-free survival; OS=Overall survival; NA=Not available; CI=Confidence interval; NOS=Newcastle-Ottawa Scale; HR=Hazard ratio